The Febrile Returner and the Off-Label Antimalarial

This is severe falciparum malaria by WHO criteria, because he has neurological involvement (confusion, GCS 14) in the presence of confirmed P. falciparum parasitaemia. Supporting features of severity: tachycardia (HR 118), hypotension (BP 102/64), tachypnoea (RR 22), and high fever. Notably, glucose is normal (4.1 mmol/L) - hypoglycaemia is a severity criterion but is absent here, so do not use it to justify the label.

Key reasoning points:

• Severity in falciparum malaria is a clinical syndrome, not just a parasite count. Any impaired consciousness, seizures, acidosis, renal impairment, pulmonary oedema, bleeding, or shock qualifies.
• A positive RDT confirms P. falciparum (most RDTs detect HRP-2 or pLDH). It does not give a parasite density, so you cannot stage severity on parasitaemia percentage - rely on clinical criteria.
• Immediate priority: parenteral artesunate (IV), given the severity. Do not wait for microscopy on Monday. Delay in severe malaria is the main driver of mortality.
• Do not give oral therapy in a confused patient (aspiration risk, unreliable absorption).
• Check and correct glucose, and monitor closely - repeat glucose and consider a glucose infusion if it trends down.

Proceed with IV artesunate now. Unlicensed status is not a barrier to using a medicine when it is clinically indicated and there is no licensed alternative of equivalent efficacy. The relevant framework is off-label / unlicensed use in the patient's best interest:

• You may prescribe an unlicensed medicine where a licensed alternative does not exist or is unsuitable, provided the decision is evidence-based and in the patient's best interest.
• Document the clinical rationale in the notes: severe malaria, no licensed IV alternative available, artesunate is the WHO-recommended first-line for severe malaria.
• Consent: explain to the patient (or, if capacity is impaired, to the next of kin and record this) what is being given and why. In an emergency with impaired capacity, treat under the doctrine of necessity/best interests and document.
• Governance: inform pharmacy retrospectively, complete an incident/medicines-use report if local policy requires, and ensure the dose is recorded accurately (weight-based).
• Do not substitute an inferior licensed drug merely to satisfy a computer flag. The clinical risk of untreated severe malaria far outweighs the administrative irregularity.

This tests whether you can distinguish a bureaucratic obstacle from a clinical contraindication.

This is a deteriorating severe malaria with possible shock and/or post-dose complication. Immediate actions:

1. Airway/breathing/circulation reassessment - GCS 10 means airway protection is at risk; call for senior/anaesthetic help and prepare for intubation if needed.
2. Check glucose immediately - hypoglycaemia is common in severe malaria (especially after treatment and in the context of quinine, though artesunate is less hypoglycaemic). Treat if <4 mmol/L with IV glucose.
3. Fluid resuscitation - cautious boluses (e.g. 250–500 mL crystalloid) with reassessment, because over-resuscitation in malaria can precipitate pulmonary oedema. Balance perfusion against this risk.
4. Consider alternative causes of deterioration: bacterial co-infection (sepsis), aspiration, delayed post-artesunate haemolysis (usually days later, not immediate), or a reaction to the drug.
5. Broad-spectrum antibiotics if bacterial sepsis cannot be excluded - co-infection is common and mortality is high.
6. Escalate to critical care, repeat parasitaemia if possible, monitor urine output and renal function.

Reasoning: in severe malaria, deterioration is multifactorial; you must not anchor on the malaria alone. The exam tests whether you prioritise ABC, glucose, and sepsis while avoiding fluid overload.